Cerity Partners’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $34M | Buy |
43,972
+9,745
| +28% | +$7.46M | 0.05% | 315 |
|
|
2025
Q4 | $26.4M | Buy |
34,227
+13,693
| +67% | +$9.3M | 0.04% | 352 |
|
|
2025
Q3 | $11.5M | Buy |
20,534
+6,676
| +48% | +$3.77M | 0.02% | 527 |
|
|
2025
Q2 | $7.28M | Sell |
13,858
-2,162
| -13% | -$1.21M | 0.01% | 658 |
|
|
2025
Q1 | $10.2M | Sell |
16,020
-40
| -0.2% | -$27.5K | 0.02% | 486 |
|
|
2024
Q4 | $12.6M | Buy |
16,060
+512
| +3% | +$430K | 0.03% | 423 |
|
|
2024
Q3 | $16.3M | Buy |
15,548
+2,423
| +18% | +$2.7M | 0.04% | 361 |
|
|
2024
Q2 | $13.8M | Sell |
13,125
-1,819
| -12% | -$1.76M | 0.04% | 345 |
|
|
2024
Q1 | $14.4M | Buy |
14,944
+3,486
| +30% | +$3.31M | 0.04% | 362 |
|
|
2023
Q4 | $10.1M | Buy |
11,458
+7,897
| +222% | +$6.5M | 0.03% | 374 |
|
|
2023
Q3 | $2.93M | Sell |
3,561
-5,890
| -62% | -$4.63M | 0.01% | 509 |
|
|
2023
Q2 | $6.79M | Buy |
9,451
+200
| +2% | +$154K | 0.03% | 437 |
|
|
2023
Q1 | $8.32M | Buy |
9,251
+44
| +0.5% | +$33.2K | 0.02% | 383 |
|
|
2022
Q4 | $6.64M | Buy |
9,207
+363
| +4% | +$268K | 0.04% | 318 |
|
|
2022
Q3 | $6.09M | Buy |
8,844
+28
| +0.3% | +$17.6K | 0.07% | 210 |
|
|
2022
Q2 | $5.21M | Buy |
8,816
+2,579
| +41% | +$1.68M | 0.06% | 244 |
|
|
2022
Q1 | $4.36M | Sell |
6,237
-2,789
| -31% | -$1.76M | 0.07% | 210 |
|
|
2021
Q4 | $5.7M | Buy |
9,026
+3,221
| +55% | +$1.98M | 0.09% | 183 |
|
|
2021
Q3 | $3.51M | Sell |
5,805
-34
| -0.6% | -$21.1K | 0.08% | 193 |
|
|
2021
Q2 | $3.26M | Buy |
5,839
+157
| +3% | +$79.5K | 0.07% | 204 |
|
|
2021
Q1 | $2.69M | Buy |
5,682
+11
| +0.2% | +$5.36K | 0.06% | 217 |
|
|
2020
Q4 | $2.74M | Buy |
5,671
+609
| +12% | +$329K | 0.09% | 174 |
|
|
2020
Q3 | $2.83M | Buy |
5,062
+249
| +5% | +$151K | 0.12% | 138 |
|
|
2020
Q2 | $3M | Buy |
4,813
+206
| +4% | +$117K | 0.17% | 112 |
|
|
2020
Q1 | $2.25M | Buy |
4,607
+508
| +12% | +$210K | 0.14% | 127 |
|
|
2019
Q4 | $1.54M | Sell |
4,099
-620
| -13% | -$209K | 0.08% | 189 |
|
|
2019
Q3 | $1.31M | Buy |
4,719
+85
| +2% | +$25.2K | 0.08% | 215 |
|
|
2019
Q2 | $1.45M | Buy |
4,634
+85
| +2% | +$28.3K | 0.09% | 189 |
|
|
2019
Q1 | $1.87M | Sell |
4,549
-285
| -6% | -$117K | 0.13% | 172 |
|
|
2018
Q4 | $1.8M | Buy |
4,834
+90
| +2% | +$32.9K | 0.12% | 165 |
|
|
2018
Q3 | $1.92M | Buy |
4,744
+157
| +3% | +$59.8K | 0.13% | 170 |
|
|
2018
Q2 | $1.58M | Buy |
4,587
+115
| +3% | +$36K | 0.12% | 184 |
|
|
2018
Q1 | $1.54M | Sell |
4,472
-254
| -5% | -$88.3K | 0.12% | 177 |
|
|
2017
Q4 | $1.78M | Sell |
4,726
-1,614
| -25% | -$654K | 0.12% | 171 |
|
|
2017
Q3 | $2.83M | Buy |
+6,340
| New | +$3.02M | 0.2% | 112 |
|
|
2017
Q2 | – | Sell |
-4,887
| Closed | -$1.89M | – | 420 |
|
|
2017
Q1 | $1.89M | Buy |
+4,887
| New | +$1.81M | 0.16% | 127 |
|
Other funds holding REGN
VCM
N
Cerity Partners's REGN Position: Q1 2026 in Review
Cerity Partners increased its Regeneron Pharmaceuticals (REGN) stake by 28% in Q1 2026, buying an estimated $7.46M and bringing the position to 43,972 shares worth $34M. The position accounts for 0.05% of the portfolio, ranked #315.
Cerity Partners first reported a position in REGN in Q1 2017 and has held it in 36 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Cerity Partners held 43,972 shares of Regeneron Pharmaceuticals worth $34M as of Q1 2026.
- Cerity Partners bought 9,745 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $7.46M.
- Regeneron Pharmaceuticals made up 0.05% of Cerity Partners's portfolio in Q1 2026, its #315 holding.
- Cerity Partners first reported a position in Regeneron Pharmaceuticals in Q1 2017 and has held it in 36 quarters since.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.